Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment

Elloumi, Héla; Houissa, Fatma; Hadj, Najet Bel; Gargouri, Dalila; Romani, Malika; Kharrat, Jamel; Ghorbel, Abdeljabbar

doi:10.3748/wjg.v13.i40.5411

Cited by 19 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all of the cases, hearing loss did not resolve completely after stopping treatment with INF- α . Similar observations have been reported in 3 other case studies [2, 6, 7]. Patients receiving either INF- α or pegylated-INF- α because of chronic hepatitis B or C suffered SSNHL and tinnitus in one or both ears and in one case gait disorder as well, following 2 to 6 months of treatment.…”

Section: Introductionsupporting

confidence: 88%

INF-αand Ototoxicity

Sharifian

Kamandi

Sima

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Introduction. INF-α is a common drug for the treatment of hepatitis B and C. Although a variety of related complications are discussed, possible ototoxic effects of this mediation are not well described. Methods and Materials. In a before-after control study, 24 patients who received INF-α for the treatment of hepatitis B and C and 30 normal controls were included. Subjective and objective ototoxicity evaluations via questionnaire, high frequency audiometry, and measuring transiently evoked otoacoustic emissions (TEOAEs) were performed one week before and one month after the prescription of the drug. Results. Subjective hearing complaint, tinnitus, and vertigo were seen in just 3 cases, which was not statistically significant (P = 0.083). In the frequency range of 4000 to 8000 Hz before (9.38 ± 1.0 and 10.7 ± 1.2, resp.) and after (17.9 ± 2.6 and 17.6 ± 2.6, resp.) one month of treatment, a significant difference (P = 0.083) was detected. Progressive decreases in amplitude of the OAE during TEOAE measurement in 1, 2, and 4 frequencies among 41.66%, 18.75 %, and 43.75% were observed, respectively. The hearing loss was seen more among older and male cases significantly. Conclusion. The results showed ototoxicity of INF-α that may encourage planning hearing monitoring in patients receiving this drug.

show abstract

Section: Introductionsupporting

confidence: 88%

INF-αand Ototoxicity

Sharifian

Kamandi

Sima

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Several cases of hearing loss during interferon therapy or combination treatment with peginterferon and antiviral for HCV infections (ribavirin) have been reported [27–30]. In our study, interferons and ribavirin were coadminstered in 78.1% (57/73 cases) of patients with hearing loss, and 21.9% (16/73 cases) patients were administered interferons alone.…”

Section: Discussionmentioning

confidence: 49%

Analysis of drug-induced hearing loss by using a spontaneous reporting system database

et al. 2019

View full text Add to dashboard Cite

Many drugs can cause hearing loss, leading to sensorineural deafness. The aim of this study was to evaluate the risk of drug-induced hearing loss (DIHL) by using the Japanese Adverse Drug Event Report (JADER) database and to obtain profiles of DIHL onset in clinical settings. We relied on the Medical Dictionary for Regulatory Activities preferred terms and standardized queries, and calculated the reporting odds ratios (RORs). Furthermore, we applied multivariate logistic regression analysis, association rule mining, and time-to-onset analysis using Weibull proportional hazard models. Of 534688 reports recorded in the JADER database from April 2004 to June 2018, adverse event signals were detected for platinum compounds, sulfonamides (plain) (loop diuretics), interferons, ribavirin, other aminoglycosides, papillomavirus vaccines, drugs used in erectile dysfunction, vancomycin, erythromycin, and pancuronium by determining RORs. The RORs of other aminoglycosides, other quaternary ammonium compounds, drugs used in erectile dysfunction, and sulfonamides (plain) were 29.4 (22.4–38.6), 18.5 (11.2–30.6), 15.4 (10.6–22.5), and 12.6 (10.0–16.0), respectively. High lift score was observed for patients with congenital diaphragmatic hernia treated with pancuronium using association rule mining. The median durations (interquartile range) for DIHL due to platinum compounds, sulfonamides (plain), interferons, antivirals for treatment of hepatitis C virus (HCV) infections, other aminoglycosides, carboxamide derivatives, macrolides, and pneumococcal vaccines were 25.5 (7.5–111.3), 80.5 (4.5–143.0), 64.0 (14.0–132.0), 53.0 (9.0–121.0), 11.0 (3.0–26.8), 1.5 (0.3–11.5), 3.5 (1.3–6.8), and 2.0 (1.0–4.5), respectively. Our results demonstrated potential risks associated with several drugs based on their RORs. We recommend to closely monitor patients treated with aminoglycosides for DIHL for at least two weeks. Moreover, individuals receiving platinum compounds, sulfonamides (plain), interferons, and antivirals for HCV infection therapy should be carefully observed for DIHL for at least several months.

show abstract

“…Ototoxicity may occur due to direct toxic effect of PEG IFNs on the ear as well as through otoimmune or hematologic mechanisms. [ 8 ]…”

Section: Discussionmentioning

confidence: 99%

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment

Gözdaş

Karabay

2015

Indian J Pharmacol

View full text Add to dashboard Cite

Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.

show abstract

Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment

Cited by 19 publications

References 12 publications

INF-αand Ototoxicity

INF-αand Ototoxicity

Analysis of drug-induced hearing loss by using a spontaneous reporting system database

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment

Contact Info

Product

Resources

About